Perinatal Outcomes in Early and Late Gestational Diabetes Mellitus After Treatment From 24-28 Weeks' Gestation: A TOBOGM Secondary Analysis.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 05 09 2023
accepted: 30 12 2023
medline: 29 2 2024
pubmed: 29 2 2024
entrez: 29 2 2024
Statut: aheadofprint

Résumé

In most gestational diabetes mellitus (GDM) studies, cohorts have included women combined into study populations without regard to whether hyperglycemia was present earlier in pregnancy. In this study we sought to compare perinatal outcomes between groups: women with early GDM (EGDM group: diagnosis before 20 weeks but no treatment until 24-28 weeks if GDM still present), with late GDM (LGDM group: present only at 24-28 weeks), and with normoglycemia at 24-28 weeks (control subjects). This is a secondary analysis of a randomized controlled treatment trial where we studied, among women with risk factors, early (<20 weeks' gestation) GDM defined according to World Health Organization 2013 criteria. Those receiving early treatment for GDM treatment were excluded. GDM was treated if present at 24-28 weeks. The primary outcome was a composite of birth before 37 weeks' gestation, birth weight ≥4,500 g, birth trauma, neonatal respiratory distress, phototherapy, stillbirth/neonatal death, and shoulder dystocia. Comparisons included adjustment for age, ethnicity, BMI, site, smoking, primigravity, and education. Women with EGDM (n = 254) and LGDM (n = 467) had shorter pregnancy duration than control subjects (n = 2,339). BMI was lowest with LGDM. The composite was increased with EGDM (odds ratio [OR] 1.59, 95% CI 1.18-2.12)) but not LGDM (OR 1.19, 95% CI 0.94-1.50). Induction of labor was higher in both GDM groups. In comparisons with control subjects there were higher birth centile, higher preterm birth rate, and higher rate of neonatal jaundice for the EGDM group (but not the LGDM group). The greatest need for insulin and/or metformin was with EGDM. Adverse perinatal outcomes were increased with EGDM despite treatment from 24-28 weeks' gestation, suggesting the need to initiate treatment early, and more aggressively, to reduce the effects of exposure to the more severe maternal hyperglycemia from early pregnancy.

Identifiants

pubmed: 38421672
pii: 154301
doi: 10.2337/dc23-1667
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : South Western Sydney Local Health District Academic Unit
Organisme : Medical Scientific Fund of the Mayor of Vienna
ID : project numbers 15205 and 23026
Organisme : National Health and Medical Research Council
ID : 1104231
Organisme : Region Örebro Research Committee
ID : 15205

Investigateurs

David Simmons (D)
N Wah Cheung (NW)
Jincy Immanuel (J)
William M Hague (WM)
Helena Teede (H)
Christopher J Nolan (CJ)
Michael J Peek (MJ)
Jeff R Flack (JR)
Mark McLean (M)
Vincent Wong (V)
Emily Hibbert (E)
Emily Gianatti (E)
Arianne Sweeting (A)
Suzette Coat (S)
Raiyomand Dalal (R)
Georgia Soldatos (G)
Suja Padmanabhan (S)
Rohit Rajagopal (R)
Victoria Rudland (V)
Jürgen Harreiter (J)
Alexandra Kautzky-Willer (A)
Herbert Kiss (H)
Helena Backman (H)
Erik Schwarcz (E)
Glynis Ross (G)
Viswanathan Mohan (V)
Ranjit Mohan Anjana (R)
Uma Ram (U)

Informations de copyright

© 2024 by the American Diabetes Association.

Auteurs

David Simmons (D)

Western Sydney University, Campbelltown, New South Wales, Australia.

Jincy Immanuel (J)

Western Sydney University, Campbelltown, New South Wales, Australia.

William M Hague (WM)

Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia.

Helena Teede (H)

Monash University, Melbourne, Victoria, Australia.

Christopher J Nolan (CJ)

Canberra Hospital and Australian National University, Canberra, Australian Capital Territory, Australia.

Michael J Peek (MJ)

Australian National University, Canberra, Australian Capital Territory, Australia.

Jeff R Flack (JR)

Bankstown-Lidcombe Hospital, Sydney, New South Wales, Australia.

Mark McLean (M)

Blacktown and Mount Druitt Hospital, Sydney, New South Wales, Australia.

Vincent Wong (V)

Liverpool Hospital and University of New South Wales, Sydney, New South Wales, Australia.

Emily J Hibbert (EJ)

Nepean Clinical School, University of Sydney, and Nepean Hospital, Sydney, New South Wales, Australia.

Alexandra Kautzky-Willer (A)

Gender Medicine Unit, Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Jürgen Harreiter (J)

Gender Medicine Unit, Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Helena Backman (H)

Department of Obstetrics and Gynecology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Emily Gianatti (E)

Department of Endocrinology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.

Arianne Sweeting (A)

Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Viswanathan Mohan (V)

Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, India.

N Wah Cheung (NW)

Westmead Hospital, Sydney, New South Wales, Australia.

Classifications MeSH